Test Preparation
This AI-powered platform helps researchers streamline their research process and enhance the reproducibility of their results.
Easily locate test preparation protocols from literature, preprints, and patents, and leverage AI-driven comparisons to identify the best protocols and products for your specific needs.
Improve the quality of your research outcomes by accessing a comprehensive resource of test preparation methods and techniques.
Simplify your test preparation workflow and elevate the impact of your work with PubCompare.ai.
Most cited protocols related to «Test Preparation»
Description of the eight empirical studies in the meta-analysis
Type of study | Setting | Design | Respondents | N |
---|---|---|---|---|
Guideline for visual disorders: levels of use [18 ] | PCHC | Cross sectional | Doctors, nurses, doctor's assistanta | 311 |
Guideline for congenital heart disorders: levels of use [19 ] | PCHC | Cross sectional | Doctors, nursesa | 210 |
Guideline for prevention of child abuse: effect of planned innovation strategy on levels of use [20 ] | PCHC | Pre-test and post-testc; experimental vs. control group | Doctors, nursesb | 302 |
Guideline for congenital heart disorders: effect of e-learning vs. traditional learning on levels of use [21 ] | PCHC | Pre-test and post-testc; experimental vs. control group | Doctors, nursesb | 317 |
Education programme for prevention of passive smoking in infants: levels of continuation of use [22 (link)] | PCHC | Cross sectional | Doctors, nursesa | 465 |
School-wide programme for prevention of bullying: effect of planned innovation strategy on levels of used | Primary schools | Pre-test and post-testc | Teachersb | 125 |
Mental health promotion programme: effect of planned innovation strategy on levels of used | Primary schools | Pre-test and two post-testsc | Teachersb | 188 |
Sex education programme: effect of planned innovation strategy on levels of use [23 (link)] | Secondary schools | Pre-test and post-testc; experimental vs. control group | Teachersb | 59 |
Total | 1977 |
PCHC, Preventive Child Health Care.
aAll PCHC organizations.
bSelected sample of PCHC organizations/schools.
cWe only used pre-test measurements.
dPublication in preparation.
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
The VENDYS DTM Test Registry includes age, sex, blood pressure, heart rate, VRI, and fingertip temperature measurements recorded during DTM tests. The Registry does not include other health related information. All DTM tests were performed in ambulatory care clinical settings. This study includes a total of 6,084 patients from 18 clinics that volunteered to submit their data to the Registry. The number of each type of medical practice is as follows: cardiology = 9, general/family practice = 4, antiaging = 3, and internal medicine = 2.
Statistical analyses were performed using MATLAB (The MathWorks, Inc., Natick, MA). Variable data were expressed as mean ± SD. VRI scores in men and women were compared using unpaired Student's t-test. Comparisons of categorical data (e.g., proportion of subjects with good VRI in men versus women) were performed using Fisher's exact test. Pairwise correlations were examined using Pearson's correlation coefficient, and correlations between VRI and multiple patient characteristics (i.e., age, sex, blood pressure, and heart rate) were evaluated using multiple linear regression analysis. p value < 0.05 was considered significant. When performing statistical comparisons, tests with missing data were excluded from the comparison. “Cold Finger Flag” was defined as the condition in which the right finger temperature at start of cuff occlusion (time 300 s) is ≤27°C. Previous DTM testing had shown that right finger t300 temperatures < 27°C often resulted in technically poor results. “Sympathetic Response Flag” was defined as the condition in which left finger temperature continuously declines (>0.5°C temperature drop over a 5-minute time period) after right arm-cuff occlusion. When evaluating VRI, tests that exhibited “Cold Finger Flag” (n = 353) or “Sympathetic Response Flag” (n = 294) were excluded from the analyses. In addition to monitoring temperature at the index finger of the right arm, we studied temperature changes at the index finger of the left (nonoccluded) arm and observed interesting signals that are currently under further investigations and not included in the results below.
Trees of simulated data were inferred with PhyML_3.0_linux64 [25 (link), 26 (link)]. We analyzed the data with a mixed-distribution model (JC+ Γ + I) and correct parameter values (α = 1.0, ρinv= 0.3), except for the categorization of the gamma distribution. The number of relative substitution rate categories was set to four (c = 4) and tree topologies and branch lengths were optimized. Maximum Likelihood analyses were performed and evaluated with a Perl pipeline. For each branch length-combination, we generated 100 data replicates and recorded the frequencies of correct and incorrect tree reconstructions using correct alignments and nearly correct substitution models (Figures
Most recents protocols related to «Test Preparation»
EXAMPLE 48
In order to determine B7-1 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.
In short, 2 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.33 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition with B7-1, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step, the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in
EXAMPLE 49
In order to determine B7-2 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.
In short, 5 μg/ml B7-muFc (Ancell, Bayport, MN, Cat #509-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 22 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in
EXAMPLE 40
In order to determine B7-1 competition efficiency of CD28 binding Nanobodies, the purified Nanobodies that showed binding in the previous binding assay were tested in an ELISA competition assay setup.
In short, 1 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 2 μg/ml CD28-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49E4) was used as a negative controle, since this Nanobody does not bind to CD28. After incubation and a wash step the CD28-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. The results are shown in
EXAMPLE 21
In order to determine PD-1 competition efficiency of B7-H1 binding Nanobodies, the positive clones of the binding assay were tested in an ELISA competition assay setup.
In short, 2 μg/ml B7-H1 ectodomain (rhB7H1-Fc, R&D Systems, Minneapolis, US, Cat #156-B7) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of PD-1-biotin was preincubated with 10 μl of periplasmic extract containing Nanobody of the different clones and a control with only PD-1-biotin (high control). The PD-1-biotin was allowed to bind to the immobilized ligand with or without Nanobody. After incubation and a wash step, PD-1 binding was revealed using a HRP-conjugated streptavidine. Binding specificity was determined based on OD values compared to controls having received no Nanobody (high control). OD values for the different Nanobody clones are depicted in
EXAMPLE 16
In order to determine competition efficiency of PD-1 binding Nanobodies, the positive clones of the previous binding assay were tested in an ELISA competition assay setup.
In short, 2 μg/ml PD-1 ectodomain (R&D Systems Cat #1086-PD, Minneapolis, US) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of biotinylated PD-L2 or B7-H1 was preincubated with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49C5) was used as a negative controle, since this Nanobody does not bind to PD-1. PD-L2 or B7-H1 without biotin (cold PD-L2 or cold B7-H1) was used as a positive controle for competition. The results are shown in
Top products related to «Test Preparation»
More about "Test Preparation"
PubCompare.ai, an AI-powered platform, offers a comprehensive solution to enhance your test preparation workflow.
This innovative tool empowers researchers to easily locate test preparation protocols from a vast repository of literature, preprints, and patents, leveraging advanced AI-driven comparisons to identify the optimal protocols and products for your specific needs.
Enhancing Reproducibility and Quality: Maximizing the quality of your research outcomes is a top priority, and PubCompare.ai is designed to help you achieve this goal.
By providing access to a comprehensive database of test preparation methods and techniques, including insights from Maxisorp microtiter plates, HRP-conjugated anti-human Fc, RhB7H1-Fc, MATLAB, PD-1 ectodomain, B7-H2 ectodomain, CellQuest software, PD-L2 ectodomain, FACSCalibur, and GF/C filters, this platform empowers you to make informed decisions and enhance the reproducibility of your results.
Streamlining Workflow and Elevating Impact: PubCompare.ai simplifies your test preparation workflow, allowing you to focus on the core aspects of your research.
With this AI-powered tool, you can easily navigate the wealth of information, identify the best protocols and products, and optimize your testing procedures.
By leveraging the insights and capabilities of PubCompare.ai, you can elevate the impact of your work and drive your research forward with confidence.
Discover the Power of PubCompare.ai: Unlock the full potential of your research with PubCompare.ai.
Explore the platform, access the comprehensive database of test preparation resources, and leverage the AI-driven comparisons to streamline your workflow and enhance the quality of your research outcomes.
Embark on a journey of discovery and success with this innovative tool at your fingertips.